Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Post by bluemoon25on Apr 20, 2011 8:46am
188 Views
Post# 18459276

News...The Richmond Club

News...The Richmond Club

CHEMAPHOR RETAINS THE RICHMOND CLUB FOR INVESTOR RELATIONS

OTTAWA, ONTARIO, April 20, 2011 - Chemaphor Inc. (TSX Venture Exchange: CFR), today announced that it retained the services of The Richmond Club to help gain exposure to potential investors and increase communication with its existing shareholders. Chemaphor plans to implement several programs to increase communication with investors and potential investors. The Richmond Club is a Toronto media firm that showcases high growth companies to its membership through its website and at investor luncheon meetings. According to the terms of their agreement, Chemaphor will pay The Richmond Club a monthly fee of $1,450 for a period of 18 months and has granted The Richmond Club 400,000 stock options. These options have an exercise price of
.10 per share, vest quarterly over a 12-month period and have an overall term of two years.

All of the foregoing matters remain subject to TSX Venture Exchange approval.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com.

About Avivagen

Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen is a wholly-owned subsidiary of Chemaphor. More information can be found at www.avivagen.com.

About Richmond Media

The Richmond Media is celebrating its 11th year of helping its members profit from the Richmond Media Orphan Lift™. Members receive information about stocks that are selected for inclusion in the Richmond Club Index, which has dramatically out-performed the Dow, S&P and the TSX Venture Exchange. To be selected, a stock must have high growth potential and be undervalued as a result of being under-noticed. These stocks tend to rise to their fair market value as a result of an 18-month Richmond Media investor exposure program which provides these worthy stocks with investor exposure through: internet exposure, direct mailings and Richmond Media luncheon events. Richmond members are brokers, fund managers, analysts and members of the media.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

###

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Investor Relations: Media Group:

Evolution Group Inc. McCormick Global Communications Sylvain Archambault Karen Sample 514-448-4887 / Toll free: 866-703-4887 519-475-6378 s.archambault@evolutiongrp.com ksample@mccormickglobal.com

www.evolutiongrp.com www.mccormickglobal.com

Bullboard Posts